Literature DB >> 3568274

Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.

Z Arlin, R Mehta, E Feldman, P Sullivan, A Pucillo.   

Abstract

Three patients with a history of supraventricular arrhythmia presented with relapse of acute leukemia. Two of the three patients were in sinus rhythm, receiving digoxin and/or verapamil daily. The third patient was in atrial fibrillation, but her heart rate was controlled with daily digoxin. All three patients received amsacrine without the occurrence of cardiac events. Although amsacrine may cause ventricular arrhythmias in the setting of hypokalemia, correction of the electrolyte abnormality permits its use in patients with a history of supraventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3568274     DOI: 10.1007/bf00254571

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.

Authors:  S S Legha; J U Gutterman; S W Hall; R S Benjamin; M A Burgess; M Valdivieso; G P Bodey
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Cardiac arrhythmia associated with AMSA in a child: a Southwest Oncology Group Study.

Authors:  A R Riela; J C Kimball; R B Patterson
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

3.  Treatment of acute leukemia with amsacrine and high-dose cytarabine.

Authors:  Z A Arlin; J Gaddipati; T Ahmed; A Mittelman; M Friedland; E Rieber
Journal:  Cancer Treat Rep       Date:  1985-09

4.  Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).

Authors:  M P Fanucchi; Z A Arlin
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

5.  Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.

Authors:  Z A Arlin; R B Sklaroff; T S Gee; S J Kempin; J Howard; B D Clarkson; C W Young
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

6.  Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).

Authors:  D D Von Hoff; D Elson; G Polk; C Coltman
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar

Review 7.  Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.

Authors:  Z A Arlin
Journal:  Cancer Treat Rep       Date:  1983-11

8.  Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.

Authors:  Z A Arlin; N Flomenberg; T S Gee; S J Kempin; C Dellaquila; R Mertelsmann; D J Straus; C W Young; B D Clarkson
Journal:  Cancer Clin Trials       Date:  1981
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.